organization · Reporting owner
Versant Vantage II, L.P.
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Century Therapeutics, Inc.IPSC · Entity 5739 | 10% owner | August 09, 2022 | August 11, 2022 |
| Tempest Therapeutics, Inc.TPST · Entity 7734 | 10% owner | August 08, 2024 | August 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Century Therapeutics, Inc.
Report date August 09, 2022 · Filed August 11, 2022
Jointly reported with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,452,014 |
Last balance in matching sequence
After 2022-08-09 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2022-08-09 · Sale · Disposed 550,000 · Balance 11,816,814 F1: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital VI, L.P. ("Versant VI"). F2: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $13.03 to $13.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3: The reportable securities are owned directly by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Each of Versant Ventures VI GP and Versant Ventures VI GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant VI, but disclaim beneficial ownership except to the extent of their pecuniary interest therein. Row 2 · 2022-08-09 · Other · Disposed 364,800 · Balance 11,452,014 F4: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant VI to its limited partners pursuant to a Rule 10b5-1 trading plan. F3: The reportable securities are owned directly by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Each of Versant Ventures VI GP and Versant Ventures VI GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant VI, but disclaim beneficial ownership except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 714,095 |
Reported balance
Holding disclosure · report date 2022-08-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 714,095 F5: The reportable securities are owned by Versant Vantage II, L.P. ("Versant Vantage II''). Versant Vantage II GP, L.P. ("Versant Vantage II GP") is the general partner of Versant Vantage II, and Versant Vantage II GP-GP, LLC ("Versant Vantage II GP-GP") is the general partner of Versant Vantage II GP. Each of Versant Vantage II GP and Versant Vantage II GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage II, but disclaim beneficial ownership except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital VI, L.P. ("Versant VI").
F2: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $13.03 to $13.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3: The reportable securities are owned directly by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Each of Versant Ventures VI GP and Versant Ventures VI GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant VI, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.
F4: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant VI to its limited partners pursuant to a Rule 10b5-1 trading plan.
F5: The reportable securities are owned by Versant Vantage II, L.P. ("Versant Vantage II''). Versant Vantage II GP, L.P. ("Versant Vantage II GP") is the general partner of Versant Vantage II, and Versant Vantage II GP-GP, LLC ("Versant Vantage II GP-GP") is the general partner of Versant Vantage II GP. Each of Versant Vantage II GP and Versant Vantage II GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage II, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.
Tempest Therapeutics, Inc.
Report date August 08, 2024 · Filed August 12, 2024
Jointly reported with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Ventures IV, LLC, Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 209,941 |
Last balance in matching sequence
After 2024-08-12 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-08-08 · Sale · Disposed 400,000 · Balance 597,940 F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.35 to $1.375, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Row 2 · 2024-08-12 · Sale · Disposed 387,999 · Balance 209,941 F3: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.10 to $1.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2: These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,171,094 |
Reported balance
Holding disclosure · report date 2024-08-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,171,094 F4: These shares are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the general partner of VVC IV and may be deemed to share voting, investment and dispositive power over the shares held by VVC IV. VV IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 7,377 |
Reported balance
Holding disclosure · report date 2024-08-08 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 7,377 F5: These shares are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the general partner of VSF IV and may be deemed to share voting, investment and dispositive power over the shares held by VSF IV. VV IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,118,644 |
Reported balance
Holding disclosure · report date 2024-08-08 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 2,118,644 F6: These shares are held of record by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the general partner of Vantage II, and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the general partner of Vantage II GP and each may be deemed to share voting, investment and dispositive power over the shares held by Vantage II. Each of Vantage II GP-GP and Vantage II GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.35 to $1.375, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2: These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
F3: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.10 to $1.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
F4: These shares are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the general partner of VVC IV and may be deemed to share voting, investment and dispositive power over the shares held by VVC IV. VV IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interests therein.
F5: These shares are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the general partner of VSF IV and may be deemed to share voting, investment and dispositive power over the shares held by VSF IV. VV IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interests therein.
F6: These shares are held of record by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the general partner of Vantage II, and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the general partner of Vantage II GP and each may be deemed to share voting, investment and dispositive power over the shares held by Vantage II. Each of Vantage II GP-GP and Vantage II GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LENZ Therapeutics, Inc.
Report date September 30, 2025 · Filed October 02, 2025
Jointly reported with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., Versant Ventures VII GP-GP, LLC
Section 16 reporting ended · disclosed 2025-10-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,050,599 |
Last balance in matching sequence
After 2025-09-30 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2025-09-30 · Sale · Disposed 49,701 · Balance 1,133,842 F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Row 3 · 2025-09-30 · Sale · Disposed 83,066 · Balance 1,050,776 F4: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.00 to $46.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Row 5 · 2025-09-30 · Sale · Disposed 177 · Balance 1,050,599 F5: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.00 to $47.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F2: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 821,752 |
Reported balance
After 2025-09-30 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2025-09-30 · Sale · Disposed 34,405 · Balance 821,752 F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 764,250 |
Reported balance
After 2025-09-30 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2025-09-30 · Sale · Disposed 57,502 · Balance 764,250 F4: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.00 to $46.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 764,127 |
Reported balance
After 2025-09-30 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2025-09-30 · Sale · Disposed 123 · Balance 764,127 F5: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.00 to $47.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F3: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 842,162 |
Reported balance
Holding disclosure · report date 2025-09-30 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 842,162 F6: These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Each of VV II GP-GP and VV II GP may be deemed to share voting, investment and dispositive power over the shares held by VV II and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
F2: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
F3: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
F4: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.00 to $46.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
F5: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.00 to $47.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
F6: These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Each of VV II GP-GP and VV II GP may be deemed to share voting, investment and dispositive power over the shares held by VV II and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein.
Turnstone Biologics Corp.
Report date August 08, 2025 · Filed August 12, 2025
Jointly reported with Versant Ventures V, LLC, Versant Venture Capital V, L.P., Versant Ophthalmic Affiliates I, L.P., Versant Affiliates Fund V, L.P., Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Capital V (Canada), LP, Versant Vantage II GP-GP, LLC, Versant Vantage II GP, L.P.
Section 16 reporting ended · disclosed 2025-08-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Versant Venture Capital V, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-08-08 · Other · Disposed 2,726,322 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F2: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis ("Dr. Davis"), a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Versant V, and each disclaims beneficial ownership of the shares held by Versant V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Venture Capital V (Canada) LP | 0 |
Reported balance
After 2025-08-08 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-08-08 · Other · Disposed 207,486 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F3: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Dr. Davis, a member of the Issuer's board of directors, is a director of Canada V GP-GP. Each of Canada V GP-GP, Canada V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Canada V, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Ophthalmic Affiliates Fund I, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2025-08-08 · Other · Disposed 90,888 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F4: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Ophthalmic, and each disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Affiliates Fund V, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2025-08-08 · Other · Disposed 82,006 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F5: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Affiliates V, and each disclaims beneficial ownership of the shares held by Affiliates, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Vantage II, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2025-08-08 · Other · Disposed 274,990 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F6: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the sole general partner of Vantage II GP. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP. Each of Vantage II GP-GP, Vantage II GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Vantage II, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest.
F2: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis ("Dr. Davis"), a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Versant V, and each disclaims beneficial ownership of the shares held by Versant V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F3: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Dr. Davis, a member of the Issuer's board of directors, is a director of Canada V GP-GP. Each of Canada V GP-GP, Canada V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Canada V, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F4: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Ophthalmic, and each disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F5: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Affiliates V, and each disclaims beneficial ownership of the shares held by Affiliates, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
F6: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the sole general partner of Vantage II GP. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP. Each of Vantage II GP-GP, Vantage II GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Vantage II, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2025 Filed Oct 2, 2025 20:40 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 123 | $47.01 | $5,782.64 |
DisclosureSEC source: 0001193125-25-228493 · ownership.xml · nonDerivative · entry 6 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 764,127 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.00 to $47.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F3 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:40 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 177 | $47.01 | $8,321.35 |
DisclosureSEC source: 0001193125-25-228493 · ownership.xml · nonDerivative · entry 5 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,050,599 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $47.00 to $47.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:40 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 57,502 | $46.41 | $2,668,483.81 |
DisclosureSEC source: 0001193125-25-228493 · ownership.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 764,250 F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.00 to $46.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:40 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 83,066 | $46.41 | $3,854,827.25 |
DisclosureSEC source: 0001193125-25-228493 · ownership.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,050,776 F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $46.00 to $46.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:40 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 34,405 | $45.35 | $1,560,428.45 |
DisclosureSEC source: 0001193125-25-228493 · ownership.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 821,752 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:40 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 49,701 | $45.35 | $2,254,173.94 |
DisclosureSEC source: 0001193125-25-228493 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,133,842 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 20:23 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 132 | $43.30 | $5,715.60 |
DisclosureSEC source: 0001193125-25-211363 · ownership.xml · nonDerivative · entry 6 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 856,157 F3 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 20:23 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 268 | $43.30 | $11,604.40 |
DisclosureSEC source: 0001193125-25-211363 · ownership.xml · nonDerivative · entry 5 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,183,543 F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 20:23 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 20,148 | $43.00 | $866,440.56 |
DisclosureSEC source: 0001193125-25-211363 · ownership.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 856,289 F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $42.25 to $43.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F3 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 20:23 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 40,907 | $43.00 | $1,759,156.45 |
DisclosureSEC source: 0001193125-25-211363 · ownership.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,183,811 F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $42.25 to $43.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 20:23 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 24,370 | $41.59 | $1,013,567.80 |
DisclosureSEC source: 0001193125-25-211363 · ownership.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 876,437 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $41.25 to $42.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 20:23 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 49,479 | $41.59 | $2,057,871.19 |
DisclosureSEC source: 0001193125-25-211363 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,224,718 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $41.25 to $42.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 26, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 1,707 | $39.50 | $67,430.26 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 12 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 900,807 F8 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.49 to $39.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4. F2 · ownership.nature: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 26, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 3,465 | $39.50 | $136,875.12 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 11 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,274,197 F8 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.49 to $39.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 26, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 21,661 | $38.97 | $844,224.48 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 10 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 902,514 F7 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.50 to $39.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4. F2 · ownership.nature: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 26, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 43,978 | $38.97 | $1,714,016.16 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 9 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,277,662 F7 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.50 to $39.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 25, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 1,058 | $39.92 | $42,236.63 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 8 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 924,175 F6 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.81 to $40.015, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. F2 · ownership.nature: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 25, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 2,149 | $39.92 | $85,790.66 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 7 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,321,640 F6 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.81 to $40.015, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 25, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 24,760 | $39.53 | $978,651.38 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 6 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 925,233 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.815 to $39.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F2 · ownership.nature: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 25, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 50,270 | $39.53 | $1,986,946.89 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 5 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,323,789 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.815 to $39.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 2,809 | $40.59 | $114,017.03 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 949,993 F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $40.50 to $40.8819, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.nature: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 5,668 | $40.59 | $230,063.55 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,374,059 F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $40.50 to $40.8819, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 10,076 | $40.03 | $403,339.26 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 952,802 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.5085 to $40.4616, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F3 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 22, 2025 Filed Aug 26, 2025 23:59 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 20,493 | $40.03 | $820,328.64 |
DisclosureSEC source: 0000950170-25-111529 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,379,727 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $39.5085 to $40.4616, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 20:51 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 15,085 | $38.56 | $581,694.19 |
DisclosureSEC source: 0000950170-25-110163 · ownership.xml · nonDerivative · entry 4 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 962,878 F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.26 to $39.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 20:51 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 30,628 | $38.56 | $1,181,049.37 |
DisclosureSEC source: 0000950170-25-110163 · ownership.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,400,220 F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $38.26 to $39.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F1 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:51 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 69,949 | $39.50 | $2,762,985.50 |
DisclosureSEC source: 0000950170-25-110163 · ownership.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 977,963 F2 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:51 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 145,051 | $39.50 | $5,729,514.50 |
DisclosureSEC source: 0000950170-25-110163 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,430,848 F1 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 16:34 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | OtherCommon Stock | 274,990 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-107403 · ownership.xml · nonDerivative · entry 5 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Vantage II, L.P. Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F1 · price: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F6 · ownership.nature: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC ("Vantage II GP-GP") is the sole general partner of Vantage II GP. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP. Each of Vantage II GP-GP, Vantage II GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Vantage II, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 16:34 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | OtherCommon Stock | 82,006 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-107403 · ownership.xml · nonDerivative · entry 4 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Affiliates Fund V, L.P. Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F1 · price: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F5 · ownership.nature: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Affiliates V, and each disclaims beneficial ownership of the shares held by Affiliates, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 16:34 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | OtherCommon Stock | 90,888 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-107403 · ownership.xml · nonDerivative · entry 3 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Ophthalmic Affiliates Fund I, L.P. Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F1 · price: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F4 · ownership.nature: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Dr. Davis, a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Ophthalmic, and each disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 16:34 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | OtherCommon Stock | 207,486 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-107403 · ownership.xml · nonDerivative · entry 2 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V (Canada) LP Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F1 · price: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F3 · ownership.nature: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Dr. Davis, a member of the Issuer's board of directors, is a director of Canada V GP-GP. Each of Canada V GP-GP, Canada V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Canada V, and each disclaims beneficial ownership of the shares held by Canada V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| August 08, 2025 Filed Aug 12, 2025 16:34 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | OtherCommon Stock | 2,726,322 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-107403 · ownership.xml · nonDerivative · entry 1 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V, L.P. Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F1 · price: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer (the "Offer")for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F2 · ownership.nature: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis ("Dr. Davis"), a member of the Issuer's board of directors, is a managing director of Versant V GP. Each of Versant V GP and Dr. Davis may be deemed to share voting and dispositive power over the shares held by Versant V, and each disclaims beneficial ownership of the shares held by Versant V, except to the extent of their respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| July 10, 2025 Filed Jul 14, 2025 20:50 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 191,376 | $34.00 | $6,506,784.00 |
DisclosureSEC source: 0000950170-25-095616 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,575,899 F1 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 27, 2025 Filed Jul 1, 2025 22:16 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 200,000 | $30.47 | $6,093,000.00 |
DisclosureSEC source: 0000950170-25-092373 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,767,275 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $30.18 to $30.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 20, 2025 Filed Jun 20, 2025 21:50 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 133,924 | $30.25 | $4,051,201.00 |
DisclosureSEC source: 0000950170-25-088604 · ownership.xml · nonDerivative · entry 3 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,967,275 F2 · ownership.direct: These shares are held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Each of VV VI GP and VV VI may be deemed to share voting, investment and dispositive power over the shares held by VVC VI and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 20, 2025 Filed Jun 20, 2025 21:50 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 100,877 | $30.35 | $3,061,616.95 |
DisclosureSEC source: 0000950170-25-088604 · ownership.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,047,912 F1 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 21:50 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 100,000 | $29.95 | $2,995,000.00 |
DisclosureSEC source: 0000950170-25-088604 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,148,789 F1 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:37 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | SaleCommon Stock | 350,000 | $29.00 | $10,150,000.00 |
DisclosureSEC source: 0000950170-25-085490 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,248,789 F1 · ownership.nature: These shares are held by Versant Venture Capital VII, L.P. ("VVC VII"). Versant Ventures VII GP-GP, LLC ("VV VII GP") is the sole general partner of Versant Ventures VII GP, L.P. ("VV VII") and VV VII is the sole general partner of VVC VII. Each of VV VII GP and VV VII may be deemed to share voting, investment and dispositive power over the shares held by VVC VII and disclaims beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 12, 2024 Filed Aug 12, 2024 20:33 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | SaleCommon Stock | 387,999 | $1.10 | $426,992.90 |
DisclosureSEC source: 0000950170-24-095675 · ownership.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,941 F3 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.10 to $1.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F2 · ownership.direct: These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:33 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | SaleCommon Stock | 400,000 | $1.35 | $540,040.00 |
DisclosureSEC source: 0000950170-24-095675 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Ventures IV, LLC · CIK 0001456589 · 10% owner Versant Venture Capital IV, L.P. · CIK 0001456590 · 10% owner Versant Side Fund IV, L.P. · CIK 0001456591 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 597,940 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.35 to $1.375, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. F2 · ownership.direct: These shares are held of record by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP, L.P. ("VV VI GP") is the general partner of VVC VI, and Versant Ventures VI GP-GP, LLC ("VV VI GP-GP") is the general partner of VV VI GP and each may be deemed to share voting, investment and dispositive power over the shares held by VVC VI. Each of VV VI GP-GP and VV VI GP disclaim beneficial ownership of such shares, except to the extent of their respective pecuniary interests therein. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 20:30 UTC | LENZ Therapeutics, Inc. LENZ · Entity 6475 | OtherCommon Stock | 598,203 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-035951 · ownership.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Venture Capital VII, L.P. · CIK 0001750266 · 10% owner Versant Ventures VII GP, L.P. · CIK 0001777655 · 10% owner Versant Ventures VII GP-GP, LLC · CIK 0001777656 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 842,162 F1 · kind: These shares were acquired pursuant to that certain Agreement and Plan of Merger by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub"), and Lenz Therapeutics, Inc., a Delaware corporation ("LENZ"), pursuant to which the Merger Sub merged with and into LENZ (the "Merger"), with LENZ continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the Merger. F1 · price: These shares were acquired pursuant to that certain Agreement and Plan of Merger by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("Merger Sub"), and Lenz Therapeutics, Inc., a Delaware corporation ("LENZ"), pursuant to which the Merger Sub merged with and into LENZ (the "Merger"), with LENZ continuing as a wholly owned subsidiary of the Issuer and the surviving corporation of the Merger. F2 · balance_after: Effective March 21, 2024, prior to the closing of the Merger, the Issuer effected a one-for-seven reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F3 · ownership.nature: These shares are held by Versant Vantage II, L.P. ("VV II"). Versant Vantage II GP-GP, LLC ("VV II GP-GP") is the sole general partner of Versant Vantage II GP, L.P. ("VV II GP") and VV II GP is the sole general partner of VV II. Each of VV II GP-GP and VV II GP disclaims beneficial ownership of the shares held by VV II, except to the extent of their respective pecuniary interests therein. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:23 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries D Preferred Stock · Derivative | 2,196,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043527 · doc4.xml · derivative · entry 26 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Vantage II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 274,990 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F6 · ownership.nature: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. Jerel C. Davis is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:23 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries C Preferred Stock · Derivative | 33,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043527 · doc4.xml · derivative · entry 25 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Affiliates Fund V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 4,216 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F5 · ownership.nature: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Affiliates, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:23 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries C Preferred Stock · Derivative | 37,283 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043527 · doc4.xml · derivative · entry 24 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Ophthalmic Affiliates Fund I, L.P. Disclosed balance after: 0 Underlying: Common Stock · 4,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F4 · ownership.nature: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:23 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries C Preferred Stock · Derivative | 85,217 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043527 · doc4.xml · derivative · entry 23 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V (Canada) LP Disclosed balance after: 0 Underlying: Common Stock · 10,669 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F3 · ownership.nature: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Jerel C. Davis is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:23 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries C Preferred Stock · Derivative | 1,119,729 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043527 · doc4.xml · derivative · entry 22 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 140,190 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F2 · ownership.nature: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:23 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries B-2 Preferred Stock · Derivative | 230,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043527 · doc4.xml · derivative · entry 21 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Affiliates Fund V, L.P. Disclosed balance after: 0 Underlying: Common Stock · 28,810 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F5 · ownership.nature: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Affiliates, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:23 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries B-2 Preferred Stock · Derivative | 255,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043527 · doc4.xml · derivative · entry 20 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Ophthalmic Affiliates Fund I, L.P. Disclosed balance after: 0 Underlying: Common Stock · 31,936 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F4 · ownership.nature: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. Jerel C. Davis is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| July 25, 2023 Filed Jul 27, 2023 16:23 UTC | Turnstone Biologics Corp. TSBX · Entity 76646 | ConversionSeries B-2 Preferred Stock · Derivative | 582,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043527 · doc4.xml · derivative · entry 19 Versant Ventures V, LLC · CIK 0001619298 · 10% owner Versant Venture Capital V, L.P. · CIK 0001589097 · 10% owner Versant Ophthalmic Affiliates I, L.P. · CIK 0001589098 · 10% owner Versant Affiliates Fund V, L.P. · CIK 0001589095 · 10% owner Versant Ventures V GP-GP (Canada), Inc. · CIK 0001619297 · 10% owner Versant Ventures V (Canada), L.P. · CIK 0001716490 · 10% owner Versant Venture Capital V (Canada), LP · CIK 0001612235 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Versant Venture Capital V (Canada) LP Disclosed balance after: 0 Underlying: Common Stock · 72,892 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date. F3 · ownership.nature: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. Jerel C. Davis is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. Each of the Reporting Persons disclaims beneficial ownership of the shares held by Canada V, except to the extent of its respective pecuniary interest therein. Dr. Davis is a director of the Issuer and files separate Section 16 reports. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.